News | June 03, 2024
Supriya Lifescience FY24 PAT up 32%
The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23
The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
_256_384.jpg)
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
Launch of 20 new medicines expected by 2030
_256_384.jpeg)
ASG Group of Eye Hospitals has 165+ branches in 85+ cities across India and abroad
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
EBITDA before special items falls 1.3 percent to € 4.41 billion
Subscribe To Our Newsletter & Stay Updated
